{"name": "FORMA Therapeutics",
 "permalink": "forma-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/forma-therapeutics",
 "homepage_url": "http://www.formatherapeutics.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2008,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@formatherapeutics.com",
 "phone_number": "617-679-1970",
 "description": "Cancer Treating Biotherapeutic Developer",
 "created_at": "Fri Jun 19 08:43:45 UTC 2009",
 "updated_at": "Sat Mar 23 09:43:13 UTC 2013",
 "overview": "\u003Cp\u003EFORMA Therapeutics is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers.\u003C/p\u003E\n\n\u003Cp\u003EFORMA\u00e2\u20ac\u2122s approach to accessing such high value drug targets, many of which pose significant challenges to conventional discovery approaches, is rooted in the concerted integration of its innovative drug discovery technologies and oncology expertise, enabling screening, discovery and rational development of a generation of small molecule drug candidates with cellular mechanisms of action. FORMA is building a pipeline of therapeutics directed at Achilles heels in human cancers, such as key targets associated with cancer stem cells, tumor cell metabolism, programmed cell death or epigenetic disease mechanisms.\u003C/p\u003E\n\n\u003Cp\u003EFORMA builds on the vision of its academic founders: Stuart Schreiber, Todd Golub and Michael Foley, each of the Broad Institute of Harvard and MIT. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of breakthrough oncology drugs.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       50],
      "assets/images/resized/0004/9585/49585v1-max-150x150.jpg"],
     [[250,
       84],
      "assets/images/resized/0004/9585/49585v1-max-250x250.jpg"],
     [[274,
       93],
      "assets/images/resized/0004/9585/49585v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$42.5M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.altassets.com/private-equity-news/article/nz17444.html",
    "source_description": "AltAssets",
    "raised_amount": 25500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 12,
    "funded_day": 1,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Lilly Ventures",
         "permalink": "lilly-ventures",
         "image":
          {"available_sizes":
            [[[150,
               71],
              "assets/images/resized/0005/5135/55135v3-max-150x150.png"],
             [[240,
               114],
              "assets/images/resized/0005/5135/55135v3-max-250x250.png"],
             [[240,
               114],
              "assets/images/resized/0005/5135/55135v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novartis Option Fund",
         "permalink": "novartis-option-fund",
         "image":
          {"available_sizes":
            [[[150,
               19],
              "assets/images/resized/0007/3160/73160v1-max-150x150.png"],
             [[250,
               32],
              "assets/images/resized/0007/3160/73160v1-max-250x250.png"],
             [[373,
               49],
              "assets/images/resized/0007/3160/73160v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Bio*One Capital",
         "permalink": "bio-one-capital",
         "image":
          {"available_sizes":
            [[[136,
               87],
              "assets/images/resized/0005/8067/58067v1-max-150x150.jpg"],
             [[136,
               87],
              "assets/images/resized/0005/8067/58067v1-max-250x250.jpg"],
             [[136,
               87],
              "assets/images/resized/0005/8067/58067v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://www.masshightech.com/stories/2009/12/14/daily60-Forma-Therapeutics-lands-3M-in-equity.html",
    "source_description": "Forma Therapeutics lands $3M in equity  ",
    "raised_amount": 3000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 12,
    "funded_day": 17,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Lilly Ventures",
         "permalink": "lilly-ventures",
         "image":
          {"available_sizes":
            [[[150,
               71],
              "assets/images/resized/0005/5135/55135v3-max-150x150.png"],
             [[240,
               114],
              "assets/images/resized/0005/5135/55135v3-max-250x250.png"],
             [[240,
               114],
              "assets/images/resized/0005/5135/55135v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novartis Option Fund",
         "permalink": "novartis-option-fund",
         "image":
          {"available_sizes":
            [[[150,
               19],
              "assets/images/resized/0007/3160/73160v1-max-150x150.png"],
             [[250,
               32],
              "assets/images/resized/0007/3160/73160v1-max-250x250.png"],
             [[373,
               49],
              "assets/images/resized/0007/3160/73160v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Bio*One Capital",
         "permalink": "bio-one-capital",
         "image":
          {"available_sizes":
            [[[136,
               87],
              "assets/images/resized/0005/8067/58067v1-max-150x150.jpg"],
             [[136,
               87],
              "assets/images/resized/0005/8067/58067v1-max-250x250.jpg"],
             [[136,
               87],
              "assets/images/resized/0005/8067/58067v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "a",
    "source_url": "http://www.masshightech.com/stories/2008/04/14/story3-Novartis-launches-startup-Forma-Therapeutics,-seeks-CEO.html",
    "source_description": "Forma raised $4 million in a Series A ",
    "raised_amount": 4000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2008,
    "funded_month": 4,
    "funded_day": 14,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Novartis Option Fund",
         "permalink": "novartis-option-fund",
         "image":
          {"available_sizes":
            [[[150,
               19],
              "assets/images/resized/0007/3160/73160v1-max-150x150.png"],
             [[250,
               32],
              "assets/images/resized/0007/3160/73160v1-max-250x250.png"],
             [[373,
               49],
              "assets/images/resized/0007/3160/73160v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2012/09/03/daily41-Forma-rakes-in-10M-fundraise.html",
    "source_description": "Forma rakes in $10M fundraise",
    "raised_amount": 10000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 9,
    "funded_day": 7,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "FORMA Therapeutics",
    "address1": "790 Memorial Drive",
    "address2": "",
    "zip_code": "02139",
    "city": "Cambridge",
    "state_code": "ME",
    "country_code": "USA",
    "latitude": 42.3595196,
    "longitude": -71.1156913}],
 "milestones":
  [{"description": "has signed a drug discovery collaboration agreement with Eisai Inc., the U.S. subsidiary of Tokyo pharmaceutical firm Eisai Co. Ltd",
    "stoned_year": 2010,
    "stoned_month": 11,
    "stoned_day": 17,
    "source_url": "http://www.masshightech.com/stories/2010/11/15/daily38-Forma-collaborating-with-Eisai-in-20M--deal.html",
    "source_text": null,
    "source_description": "Forma collaborating with Eisai in $20M+ deal",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "FORMA Therapeutics",
      "permalink": "forma-therapeutics"}},
   {"description": "FORMA Therapeutics Announces Collaboration with Boehringer Ingelheim to Develop Novel Oncology Drugs",
    "stoned_year": 2012,
    "stoned_month": 1,
    "stoned_day": 5,
    "source_url": "http://formatherapeutics.com/news_events/forma-therapeutics-announces-collaboration-with-boehringer-ingelheim-to-develop-novel-oncology-drugs/",
    "source_text": "",
    "source_description": "FORMA Therapeutics Announces Collaboration with Boehringer Ingelheim to Develop Novel Oncology Drugs",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "FORMA Therapeutics",
      "permalink": "forma-therapeutics"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        111],
       "assets/images/resized/0004/9586/49586v1-max-150x150.jpg"],
      [[250,
        185],
       "assets/images/resized/0004/9586/49586v1-max-250x250.jpg"],
      [[450,
        334],
       "assets/images/resized/0004/9586/49586v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}